A landmark study from Singapore opens new doors for treating rare, aggressive cancers. But for patients in Asia, China is emerging as a compelling alternative worth considering.
On April 1, 2026, researchers at the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School published findings in the journal Science Translational Medicine that are drawing serious attention from oncologists worldwide. Their study takes a deep dive into BAP1 — a tumor suppressor gene whose inactivation drives some of the most difficult-to-treat cancers known to medicine.
BAP1 mutations aren't rare in the way you'd define a rare disease. They're found in a meaningful proportion of several aggressive cancers: mesothelioma (particularly common in the lining of the lungs), uveal melanoma (the most common eye cancer in adults), cholangiocarcinoma (bile duct cancer), and clear cell renal cell carcinoma (a stubborn kidney cancer). For patients carrying these mutations, treatment options have historically been limited and outcomes poor.
What the Singapore team did differently was look across all four cancer types simultaneously — something most research tends not to do. By studying cell lines, organoids, and animal models together, they traced exactly how BAP1 loss drives cancer progression at the molecular level. The result is a new therapeutic strategy aimed at slowing disease advancement, not just managing symptoms.
It's still early — the team plans preclinical and clinical studies next. But the molecular roadmap they've produced could accelerate drug development significantly. For patients with these cancer types, this is one of the more hopeful pieces of research to emerge this year.
China has been moving fast in precision oncology. Over the past few years, the country has built out an impressive infrastructure for targeted cancer therapies, with several initiatives directly relevant to the kinds of cancers the Singapore study addresses.
For mesothelioma specifically, the picture in China is evolving. Historically, malignant mesothelioma has been underdiagnosed and underreported in China, but researchers have flagged a rising incidence trend over the past two decades — driven partly by lagged effects from asbestos exposure. This has pushed Chinese thoracic oncology centers to develop more experience with multimodal treatment approaches, combining surgery, chemotherapy, and increasingly, immunotherapy.
China's National Medical Products Administration (NMPA) has been accelerating approvals of targeted therapies, and several domestic trials are active for BAP1-related approaches. Institutions like the Shanghai Cancer Center, Peking Union Medical College Hospital, and Fudan University Cancer Hospital have invested heavily in molecular profiling and genomic medicine — meaning patients can now get their tumor's full genomic portrait done domestically, which is essential for identifying BAP1 and other mutations.
For cholangiocarcinoma and uveal melanoma — both notoriously difficult cancers — China's CAR-T and TCR-T cell therapy programs have expanded rapidly. While much of the global CAR-T buzz has centered on blood cancers, Chinese biotech companies have been pushing the technology into solid tumors. Early data from trials at centers like Zhejiang University and the Chinese Academy of Medical Sciences has shown promise for cholangiocarcinoma patients with specific antigen profiles.
On the heavy ion therapy front — particularly relevant for radiation-resistant tumors like mesothelioma and cholangiocarcinoma — China now operates multiple carbon ion therapy centers, including facilities in Shanghai, Wuwei, and Lanzhou. These systems offer a form of radiation that's better able to target dense, resistant tumors while sparing surrounding tissue. Singapore's public hospitals, by contrast, do not yet have heavy ion capability on-island.
| Factor | Singapore | China |
|---|---|---|
| Research Leadership | NCCS + Duke-NUS producing cutting-edge basic research; strong publication output in top journals | Rapidly growing clinical trial ecosystem; major genomic profiling programs at top tier hospitals |
| BAP1 Testing Availability | Widely available at major public and private hospitals; NCCS offers comprehensive genomic profiling | Increasingly available at top cancer hospitals; growing access through domestic NGS panels |
| Targeted Therapy Access | Fast access to globally approved PARP inhibitors and immunotherapy; JCI-accredited hospital system | NMPA approvals accelerating; domestic biosimilars and combination immunotherapy trials expanding |
| CAR-T for Solid Tumors | Primarily focused on hematologic malignancies; limited solid tumor CAR-T programs | Active solid tumor CAR-T trials for cholangiocarcinoma, liver cancer, and other GI cancers; growing pipeline |
| Heavy Ion / Carbon Therapy | Not available domestically; patients referred overseas | Multiple operational carbon ion centers; approved for treating resistant solid tumors |
| Mesothelioma Surgery | Limited volume due to small population; expertise concentrated at Singapore General Hospital | Higher surgical volumes at major thoracic centers in Beijing, Shanghai, Guangzhou; more institutional experience |
| Estimated Cost (Complex Cancer) | USD $80,000–$200,000+ annually for advanced treatment; no universal public coverage for foreigners | USD $25,000–$70,000 for comparable treatment packages at top private or semi-private hospitals |
| Medical Tourism Support | Mature ecosystem: facilitators, translators, concierge services; English widely spoken | Growing infrastructure for international patients; English-language services expanding at major hospitals |
| Wait Times | Typically 1–3 weeks for specialist consultation at private hospitals | Often 3–7 days at top hospitals; some international patient departments can arrange faster intake |
| Insurance & Payment | Private insurance required for most treatments; no national health insurance for foreign patients | International patient departments accept self-pay and international insurance; some hospitals have package pricing |
External Sources:
Our team can help you understand your options, arrange genomic testing, and connect you with the right specialists — often within days, not weeks.
Get a Free Consultation